Quote this publication Share Print

AFINITOR

-
Opinions on drugs - Posted on Mar 28 2012

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication: “treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease”.

-


Clinical Benefit

Substantial

The actual benefit of AFINITOR is substantial.


Clinical Added Value

minor

AFINITOR provides a minor IAB (level IV) in terms of efficacy in the therapeutic management of patients with advanced neuroendocrine tumours of pancreatic origin.


Contact Us

Évaluation des médicaments

See also